breakthrough-cancer-pain-6 subsys coupon

What is SUBSYS?

Spray Technology

SUBSYS is the Only Non-Ionized Fentanyl in a Form Ready for Absorption

This unique compact single-unit fentanyl spray device delivers 0.1mL of an oral solution.

SUBSYS is formulated to be dispersed over the broad permeable sublingual mucosa.

There is no need for disintegration, dissolution or pH adjustment after dosing.

SUBSYS contains xylitol, a natural sugar-free sweetener that:

  • Does not promote dental caries
  • Does not require insulin to be metabolized
Fentanyl Sublingual Spray Delivery

Patients Should Follow These Necessary Steps for Taking SUBSYS

SUBSYS is a unique spray technology formulated to be sprayed underneath the tongue for absorption of fentanyl across the sublingual mucosa. SUBSYS is conveniently administered in seconds.

How to use video
  • How to Use SUBSYS Sublingual Spray

    Remove the SUBSYS spray unit from the blister package by cutting the dashed line with scissors.

  • How to Use SUBSYS Sublingual Spray

    Before using SUBSYS, swallow any saliva in your mouth, and hold the SUBSYS spray unit upright using your index and middle fingers and thumb.

  • How to Use SUBSYS Sublingual Spray

    Point the nozzle into your mouth and under your tongue. The nozzle may rest on the middle of your lower teeth for stability.

  • How to Use SUBSYS Sublingual Spray

    Tilt the device at an approximate 45-degree angle, and raise your tongue towards the roof of your mouth.

  • How to Use SUBSYS Sublingual Spray

    Squeeze your finger and thumb together to spray SUBSYS under your tongue.

  • How to Use SUBSYS Sublingual Spray

    Hold the medicine under your tongue for 30-60 seconds. Do not spit out any of the medicine, and do not rinse out your mouth.


Warnings and Precautions

  • Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of SUBSYS, the risk is greatest during the initiation of therapy or following a dosage increase.
  • In cancer patients with mucositis, exposure to SUBSYS was greater than in patients without mucositis. For patients with Grade 1 mucositis, the increased maximum serum concentration and overall exposure requires closer monitoring for respiratory depression and central nervous system depression, particularly during initiation of therapy with SUBSYS
  • For patients with Grade 2 mucositis or higher, avoid the use of SUBSYS unless the benefits outweigh the potential risk of respiratory depression from increased exposure
Breakthrough Cancer Pain Relief
Breakthrough Cancer Pain Relief